Physician profile
Robert James Bowes
NPI 1588605372
$4,120.72
in general payments reported to CMS, 2019-2025
32 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $206 · 2021: $527 · 2022: $1,365 · 2023: $745 · 2024: $387 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $1,316.00 | 2019-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Abbvie INC. | $675.00 | 2019-2024 | Viberzi, Lo Loestrin Fe |
| Momentis Surgical INC. | $500.00 | 2022 | |
| Astellas Pharma US INC | $239.05 | 2019-2023 | Veozah |
| Gynesonics, INC. | $223.38 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Aspira Women'S Health INC | $198.21 | 2022-2024 | Ova1 |
| Amag Pharmaceuticals, INC. | $84.99 | 2019-2020 | |
| Daiichi Sankyo INC. | $82.91 | 2019-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $77.99 | 2019-2022 | |
| Channel Medsystems, INC. | $61.17 | 2025 | |
| Meditrina | $59.65 | 2023 | |
| Axonics, INC. | $57.97 | 2022 | |
| Organon LLC | $55.35 | 2021-2025 | Nexplanon |
| Allergan, INC. | $52.22 | 2019-2022 | |
| Biogen, INC. | $45.13 | 2024 | Zurzuvae |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $40.25 | 2022 | |
| Myovant Sciences INC. | $36.84 | 2021 | |
| Coloplast Corp | $36.04 | 2020 | |
| Merck Sharp & Dohme LLC | $33.28 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.01 | 2022 | |
| Minerva Surgical, INC | $27.15 | 2023 | |
| Mayne Pharma Commercial LLC | $25.39 | 2025 | |
| Exeltis, USA INC. | $24.28 | 2022 | |
| Medtronic, INC. | $19.84 | 2023 | Truclear |
| Pacira Pharmaceuticals Incorporated | $19.17 | 2022 | |
| Becton, Dickinson and Company | $17.59 | 2023 | Bd Onclarity |
| Vertical Pharmaceuticals, LLC | $15.85 | 2020 | |
| Ibsa Pharma INC. | $14.67 | 2022 | |
| Coopersurgical, INC. | $14.49 | 2024 | Paragard T 380a |
| Mallinckrodt Enterprises LLC | $14.08 | 2019 | |
| Evofem Biosciences, INC. | $12.03 | 2022 | |
| Roche Diagnostics Corporation | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bowes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.